• May2

    Cancer Genetics Launches Proprietary Microarray for Kidney Cancer

      UroGenRA™-Kidney was designed and developed at Cancer Genetics to assist in the diagnosis and treatment selection of kidney cancer. Clinical Laboratory Improvement Amendments (CLIA) & New York State approvals of the microarray as a laboratory developed test (LDT) expand CGI’s menu of proprietary molecular diagnostic tests for urogenital and hematological cancers. Rutherford, May 2, […]

    » Continue Reading